Mageb2 binding constructs

TWI931352BActive Publication Date: 2026-07-11AMGEN INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW110118126
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-21
Filing Date
2021-05-19
Publication Date
2026-07-11
Estimated Expiration
2041-05-18
Patent Text Reader

Abstract

This invention relates to an antibody construct comprising a domain that binds to the HLA-complexed MAGEB2 peptide and, optionally, a domain that binds to CD3. Furthermore, this invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide, and host cells transformed or transfected with the polynucleotide or the vector. Additionally, this invention provides a method for producing the antibody construct of this invention, medical uses of the antibody construct, and a kit comprising the antibody construct.
Need to check novelty before this filing date? Find Prior Art

Claims

1. An isolated antibody construct, wherein the antibody construct comprises: a) a VH region comprising CDR-H1, CDR-H2, and CDR-H3 and a VL region comprising CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO: 361, CDR-H2 has the amino acid sequence of SEQ ID NO: 362, CDR-H3 has the amino acid sequence of SEQ ID NO: 363, CDR-L1 has the amino acid sequence of SEQ ID NO: 145, CDR-L2 has the amino acid sequence of SEQ ID NO: 146, and CDR-L3 has the amino acid sequence of SEQ ID NO: 147; or b) The first part contains the VH region of CDR-H1, CDR-H2, and CDR-H3 and the VL region of CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO: 331, CDR-H2 has the amino acid sequence of SEQ ID NO: 332, CDR-H3 has the amino acid sequence of SEQ ID NO: 333, CDR-L1 has the amino acid sequence of SEQ ID NO: 115, CDR-L2 has the amino acid sequence of SEQ ID NO: 116, and CDR-L3 has the amino acid sequence of SEQ ID NO: 117; or c) the second part contains the VH region of CDR-H1, CDR-H2, and CDR-H3 and the third part contains the VL region of CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO:

331. The amino acid sequence of SEQ ID NO: 337, the amino acid sequence of SEQ ID NO: 338 of CDR-H2, the amino acid sequence of SEQ ID NO: 339 of CDR-H3, the amino acid sequence of SEQ ID NO: 121 of CDR-L1, the amino acid sequence of SEQ ID NO: 122 of CDR-L2, and the amino acid sequence of SEQ ID NO: 123 of CDR-L3.

2. The antibody construct of claim 1, wherein the antibody construct comprises: a) a VH region having an amino acid sequence of SEQ ID NO: 577 and a VL region having an amino acid sequence of SEQ ID NO: 576; or b) a VH region having an amino acid sequence of SEQ ID NO: 557 and a VL region having an amino acid sequence of SEQ ID NO: 556; or c) a VH region having an amino acid sequence of SEQ ID NO: 561 and a VL region having an amino acid sequence of SEQ ID NO:

560.

3. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO: 361, CDR-H2 has the amino acid sequence of SEQ ID NO: 362, CDR-H3 has the amino acid sequence of SEQ ID NO: 363, CDR-L1 has the amino acid sequence of SEQ ID NO: 145, CDR-L2 has the amino acid sequence of SEQ ID NO: 146 and CDR-L3 has the amino acid sequence of SEQ ID NO:

147.

4. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO: 331, CDR-H2 has the amino acid sequence of SEQ ID NO: 332, CDR-H3 has the amino acid sequence of SEQ ID NO: 333, CDR-L1 has the amino acid sequence of SEQ ID NO: 115, CDR-L2 has the amino acid sequence of SEQ ID NO: 116 and CDR-L3 has the amino acid sequence of SEQ ID NO:

117.

5. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, wherein CDR-H1 has the amino acid sequence of SEQ ID NO: 337, CDR-H2 has the amino acid sequence of SEQ ID NO: 338, CDR-H3 has the amino acid sequence of SEQ ID NO: 339, CDR-L1 has the amino acid sequence of SEQ ID NO: 121, CDR-L2 has the amino acid sequence of SEQ ID NO: 122 and CDR-L3 has the amino acid sequence of SEQ ID NO:

123.

6. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region having an amino acid sequence of SEQ ID NO: 577, and a VL region having an amino acid sequence of SEQ ID NO:

576.

7. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region having an amino acid sequence of SEQ ID NO: 557, and a VL region having an amino acid sequence of SEQ ID NO:

556.

8. The antibody construct of claim 1, wherein the antibody construct comprises: a VH region having an amino acid sequence of SEQ ID NO: 561, and a VL region having an amino acid sequence of SEQ ID NO: 560.